With the rise of immunotherapies for cancer, the limitations of RECIST-based evaluation are becoming more important.
As we celebrate medical and scientific advances, we must also recognize the challenges in how we evaluate and deliver new treatments.
Innovation is not a destination; it is a journey defined by curiosity, courage, and a relentless commitment to learning.
CM-UK--2500026DOP: August 2025